Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CureXcell in Diabetic Foot Ulcers
NCT01421966Phase 3Completed
- Sponsor
- Macrocure Ltd.
- Start
- Aug 2011
- Primary completion
- Feb 2015
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of CureXcell in diabetic foot ulcer (DFU) (2 arms), sponsored by Macrocure Ltd. Primary endpoint: Proportion of patients with complete healing/closure of their target ulcer at 20 weeks. Started Aug 2011; status: completed.
02
Drugs
CureXcell
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT01421966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01421966.